Connection Between Dementia and Chronic Lower Back Pain Treatment

Gabapentin Linked to Increased Risk of Dementia

A commonly prescribed medication for nerve pain and epilepsy, gabapentin, has been associated with a rise in dementia and mild cognitive impairment cases.

Researchers from Case Western Reserve University School of Medicine, Arizona State University, and MetroHealth Medical Center analyzed data from 26,416 patients suffering from chronic lower back pain. They specifically looked into how prescriptions of gabapentin correlated with dementia diagnoses.

Patients who received six or more prescriptions of gabapentin showed a considerable uptick in dementia risk. The findings revealed those individuals were 29 percent more likely to be diagnosed with dementia and a staggering 85 percent more likely to face mild cognitive impairment (MCI) within a decade.

The risk appeared to be more pronounced among individuals aged 35 to 49, and it increased alongside the number of prescriptions issued. While this study doesn’t definitively link gabapentin to increased dementia risk, experts suggest physicians should monitor their patients who are taking the drug closely.

According to the researchers, “Gabapentin prescription in adults with chronic low back pain is associated with increased risk of dementia and cognitive impairment, particularly in non-elderly adults.” They emphasized the importance of ongoing cognitive assessments in patients prescribed gabapentin.

Gabapentin, marketed under various brand names, including Neurontin, has gained popularity as a less addictive alternative to opioids. Nonetheless, it can still cause some known side effects, like mood swings and allergic reactions.

This isn’t the first time that researchers have looked at the potential links between gabapentin and dementia; however, earlier studies have produced inconsistent results regarding the validity of these concerns.

Although the sample size for this study is relatively large, it predominantly focused on a single demographic—people with chronic lower back pain. A previous investigation conducted in 1997 found no significant connection between gabapentin and cognitive decline in epilepsy patients, which underscores the need for broader research.

These conflicting findings might imply that unique factors among back pain patients receiving gabapentin could enhance their risk of dementia, perhaps due to specific inflammatory issues.

Gabapentin affects key brain communication pathways to alleviate pain or reduce seizure frequency. Consequently, there’s apprehension that it might also disrupt neural connections in ways that could contribute to dementia—a concern that this latest study seems to support.

Researching dementia is complex, given the multitude of influencing factors. Yet, each study gets us a little closer to understanding how the brain deteriorates over time.

Ultimately, the researchers hope this study will encourage more investigations to explore whether gabapentin has a causal impact on dementia and what the underlying mechanisms may be.